Onkológia 1/2008
PHARMACOECONOMIC EVALUATION OF DOCETAXEL IN INDUCTION CHEMOTHERAPY OF LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
The question, whether induction chemotherapy followed by concurrent chemoradiation therapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN), was the goal of the cost effectivness analysis, presented on 2007 ASCO Annual Meeting Proceedings1. Economic evaluation was based on the findings from randomised clinical TAX 324 trial2. The docetaxel treatment regimen used in the study, is approved in the European Union also due to this trial and can be of interest also in the Slovak conditions.
Keywords: carcinoma of the head and neck, induction chemotherapy, pharmacoeconomic evaluation, cost effectiveness, docetaxel
